Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma.
Becker JC, Andersen MH, Hofmeister-Müller V, Wobser M, Frey L, Sandig C, Walter S, Singh-Jasuja H, Kämpgen E, Opitz A, Zapatka M, Bröcker EB, Thor Straten P, Schrama D, Ugurel S.
Becker JC, et al. Among authors: brocker eb.
Cancer Immunol Immunother. 2012 Nov;61(11):2091-103. doi: 10.1007/s00262-012-1266-9. Epub 2012 May 8.
Cancer Immunol Immunother. 2012.
PMID: 22565484
Free PMC article.
Clinical Trial.